SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-043347
Filing Date
2024-04-10
Accepted
2024-04-10 16:05:13
Documents
13
Period of Report
2024-04-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prld-20240408.htm   iXBRL 8-K 58144
2 EX-10.1 prld-ex10_1.htm EX-10.1 79686
3 EX-10.2 prld-ex10_2.htm EX-10.2 76281
  Complete submission text file 0000950170-24-043347.txt   383310

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20240408.xsd EX-101.SCH 44964
16 EXTRACTED XBRL INSTANCE DOCUMENT prld-20240408_htm.xml XML 4721
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

IRS No.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39527 | Film No.: 24835779
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)